Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05372523 · ClinicalTrials.gov registry record
Senseye's OBCI Diagnostic Tool for PTSD
A clinical trial, sponsored by Senseye.
- Terminated
- Registry status
- 61
- Enrollment target
NCT05372523: Clinical Trial study, sponsored by Senseye.
NCT05372523 is a clinical trial that was terminated before completion, run by Senseye. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05372523 was terminated before completion, sponsored by Senseye.
- TERMINATED
- Registry status
- 61 participants
- Enrollment target
Study Summary
This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. A total of 68 adults will be included in the study with a follow-up time point of 9 weeks post-initial intervention.
Primary Outcome
Assessments for the presence and severity of PTSD symptoms will be compared between the Senseye tool and the gold-standard measures for percent agreement.
Interventions
- DIAGNOSTIC_TEST CAPS-5 Assessment
- DIAGNOSTIC_TEST Senseye OBCI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-04-25 |
| Est. Completion | 2023-01-11 |
Why NCT05372523 stopped before completion
NCT05372523 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which CAPS-5 Assessment is the first listed.
NCT05372523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05372523 about?
NCT05372523 is a clinical study titled "Senseye's OBCI Diagnostic Tool for PTSD". This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. A total of 68 adults will be included in the study wi...
What is the current status of trial NCT05372523?
This trial is currently terminated. The enrollment target is 61 participants. The study started on 2022-04-25. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT05372523?
The interventions under investigation include: CAPS-5 Assessment (DIAGNOSTIC_TEST), Senseye OBCI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05372523?
This trial is sponsored by Senseye, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI